Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

441 Pages (Click to Jump) V  < 1 2 3 4 5 > »    
 
  
Reply to this topic

KZA, KAZIA THERAPEUTICS LIMITED
applefoot
post Posted: Mar 21 2014, 04:06 AM
  Quote Post


Posts: 192
Thanks: 83


Hi Guys.

Looks like a new CEO blog posting on the background to the latest Trx-1 news.

It's well worth a read.

Apples


http://www.novogen.com/ceo-postings/2014/3...20-march-2014-1

 
applefoot
post Posted: Dec 20 2013, 08:21 AM
  Quote Post


Posts: 192
Thanks: 83


New Global Collaboration with Cornell University on Brain Cancer has just been announced.

Almost exactly a year to the day that Prof. Kelly took over the reins again and this good news is just the latest in a long line of such PR's over the last year.

Seasons Greetings to anyone still reading this board. <grin>

Apples
NOVOGEN LTD ­ ACN 063 259 754 16-20 Edgeworth David Ave, Hornsby, NSW, 2077 P: +61 (0) 2 9476 0344 - F: +61 (0) 2 9476 0388 www.novogen.com NOVOGEN LIMITED
(ASX: NRT) ASX RELEASE
20 December 2013

Novogen Announces Establishment of Global Collaboration to Drive The
Development of Drugs to Treat Brain Cancer

20 December 2013, Sydney, Australia: Novogen Limited, an oncology drug development
company, announced today the signing of a Sponsored Research Agreement with Cornell
University. The Weill Cornell Medical College (WCMC) in New York will become the
cornerstone of a collaboration across Europe, US, Asia and Australia involving universities
and biotechnology companies seeking a treatment capable of delivering long-term remission
for the main form of primary brain cancer, glioblastoma multiforme (GBM).

The research program is focused on the super-benzopyran drug, Trilexium (Trx).

The brain cancer program parallels that of the Company's efforts in the area of ovarian cancer
through its joint venture, CanTx Inc, with Yale University.

CanTx has identified a Trilexium derivative (Trx-1) as having equipotent killing ability of both
ovarian cancer stem cells and ovarian cancer somatic cells, raising the prospect for the first
time of being able with the one agent to kill the full hierarchy of cells within an ovarian cancer.
The CanTx strategy is to bring Trx-1 into the clinic in the near-term as a generic treatment for
late-stage ovarian cancer, but then to use the Trx pharmacophore to create a panel of drugs
capable of killing ovarian cancer cells with specific genotypes, a further unique feature of this
technology platform.

The brain cancer program has the same R&D and commercial objectives. The near-term goal
is to bring Trilexium into the clinic as a generic treatment for GBM that has failed to respond
to Temozolomide, the only drug approved for GBM. The longer-term goal is to identify a panel
of drugs capable of providing a personalized approach to GBM chemotherapy.

The program is based on the high potency of Trilexium against GBM cells, with both GBM
stem cells and somatic cells being killed at equivalent dosages.
Progression of GBM following radiotherapy and chemotherapy is believed to result from the
regrowth of cancer stem cells that are chemo-resistant. Recurrent tumor cells, like their parent
GBM stem cells, are highly drug-resistant and with increased aggression, accounting for the
poor prognosis associated with GBM.

Dr David Brown, Novogen Group CSO, said, "The collaborative effort to date has focused on
bringing Trilexium into the clinic for the treatment of GBM, and that goal will continue with
the aim of bringing that agent into the clinic in early 2015."

"The expansion of the collaboration to include Cornell takes the program to the next level,
which is to achieve personalized chemotherapy for patients with GBM. The objective is to
identify a panel of Trx analogs that target individual GBM mutations within the genotype
spectrum that characterises GBM malignancies. That data then will inform our clinical
objective which is to match the best drug candidate to an individual tumor genotype."

"WCMC has particular skills in identifying the genotype of explants from fresh biopsies of
GBM tumors. We will be utilizing this ability to screen Trilexium analogs for activity against
a wide range of individual tumors," Dr Brown added.


About Glioblastoma
Glioblastoma multiforme is the most common and aggressive form of primary brain tumor.
Worldwide, in developed countries, an estimated 3.5 cases per 100,000 people are diagnosed
per year. Glioblastoma is one of the cancers most resistant to treatments and is associated with
extremely poor prognosis. Despite therapeutic intervention (surgery/radiation/chemotherapy),
glioblastoma remains a devastating disease with a median 2-year survival rate in the range of
10­25%.

About Novogen
Novogen Ltd is a public, Australian biotechnology company whose shares trade on both the
Australian Securities Exchange (`NRT') and NASDAQ (`NVGN'). The Company is based in
Sydney, Australia, and with a US office in New Haven, Connecticut. The Company has two
main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins
(ATM). SBP drugs target cancer stem cells and are being developed for the treatment of
ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being
developed for the treatment of melanoma, prostate cancer and neuroblastoma. Novogen has
entered into a joint venture with Yale University known as CanTx Inc with the aim of
developing personalized chemotherapy for patients with ovarian cancer.

 
applefoot
post Posted: Nov 24 2013, 07:36 AM
  Quote Post


Posts: 192
Thanks: 83


Here's a link to a short news item on Australian TV about the recent announcement of the effect the new cancer compounds are having on the cells of muscular dystrophy.

Doc Kelly has a short piece to camera but it mainly features a young boy with the disease.

http://au.news.yahoo.com/video/watch/19985...ncer-sufferers/

Good bit of early publicity for the company.... let's hope there is lots more to come both on the cancer treatments and degenerative diseases too.

Cheers

Apples

 
Xroutersix
post Posted: Nov 17 2013, 12:57 AM
  Quote Post


Posts: 83
Thanks: 4


In Reply To: applefoot's post @ Nov 16 2013, 10:29 PM

Thanks Apples, I was hoping to go to the Boston meeting in December ,but I doubt it. I'm retired now and caring for my disabled kid with the wife.. Still, life is good.. Thanks again mate,Strik

 
applefoot
post Posted: Nov 16 2013, 10:29 PM
  Quote Post


Posts: 192
Thanks: 83


Hi Guys,

I asked a mate who went to the AGM to give us a report on what was said. The following is from the notes made at the meeting.

I take particular note of the mention that the acquisition of the Triaxial technology was the turning point. I know a lot of us already appreciate this but some of the gripers should realise that without that event having taken place...and with all the assets sold off or moved into MEIP....Novogen would be worth just pennies by now and with no future to look forward to.

What the new team have accomplished IN LESS THAN A YEAR... is absolutely incredible in my view.

Some other excellent information in here also. Good points for discussion.

Cheers

Apples


AGM report

Graham Kelly noted that less than 12 months ago Novogen had no assets except for its dual-listing; and virtually no money. The acquisition of Triaxial was the turning point.

GK said that he would judge success by the number of patents the company owned as each patent allowed 20 to 25 years exclusive use.

The company intended to lodge a lot more applications before the end of the 2013, which is pretty significant when you think about it.

These applications will each cover a family of drugs and should prevent competitors making similar drugs once the manufacturing process becomes public.

Remember also that an application cannot be lodged unless the inventor has actually made the claimed drugs, so they have been very busy on this.

GK said that the company had raised about $7 million and that Hudson Bay had proven to be a good partner that had been able to sell their shares off-market to Canadian interests, and in the process proved that it was not toxic finance.

Novogen will need to raise more funds over time to fund its expanding portfolio but does not intend to take any more tranches from Hudson Bay under the current deal.

After the Resolutions had been passed, a power-point presentation set out the 10-year vision of the company. (That PP Presentation is now on the Novogen website from the "News" section)

Shareholders seemed to be happy with progress over the last year.

 
arty
post Posted: Nov 15 2013, 10:55 AM
  Quote Post


Posts: 13,078
Thanks: 3381


In Reply To: applefoot's post @ Nov 14 2013, 10:12 PM

... as I was saying:

Attached Image



a day or two behind PSY:
Attached image(s)
Attached Image

 




--------------------
I trade daily, but I am not a licensed adviser. Whether you find my ideas reasonable or not: The only person responsible for your actions is YOU.
I follow two rules: (1) There are no sacred truths. All assumptions must be critically examined. Arguments from authority are worthless. (2) Whatever is inconsistent with observed facts must be discarded or revised. We must understand the Market as it is and not confuse how it is with how we wish it to be. (inspired by Carl Sagan)
 


applefoot
post Posted: Nov 14 2013, 10:12 PM
  Quote Post


Posts: 192
Thanks: 83


Well.... the good news just keeps on coming.

This is the press release that was issued in Australia last night. The news is potentially MONUMENTAL.... and the share price rose on the release.

The company holds its AGM on Friday (tomorrow) in Sydney Australia... so I guess that will be very well attended. The company is also planning a series of Investor Presentations in the USA during January.

If you need more information on any of the above visit the website www.novogen.com

Pity there are so few people on this board to read the good news. Good to see you two new guys though.<grin>

Apples


ASX RELEASE
14 November 2013

Novogen Announces Important Discovery in Program to Develop Drugs Against Genetic and Degenerative Disorders
Novogen compounds currently undergoing screening against 30 genetic disorders including Cystic Fibrosis and Huntington’s Disease

Novogen Limited (ASX:NRT, NASDAQ: NVGN) is engaged in a pilot program aimed at the breakthrough development of drugs to treat a wide range of genetic and non-genetic degenerative diseases including muscular dystrophy, motor neurone disease, Huntington’s Disease, cystic fibrosis and Alzheimer’s Disease.

The program has returned positive findings, with a pilot drug proving to be highly cytotoxic against the initial screen: stem cells from a neuromuscular dystrophy disease.

The program is being conducted in collaboration with Australian company, Genea Biocells, which has pioneered the isolation and in vitro differentiation of stem cells from embryos with genetic disorders and now holds the world’s largest bank of pluripotent human embryonic stem cells with over 100 lines covering some 30 different diseases.

The program is based on the discovery that one of the Novogen drug families induces apoptosis in cancer stem cells in a highly potent manner, with the company to date focusing that biological property on the development of anti-cancer drugs.

Novogen CEO, Dr Graham Kelly, said that the success of the cancer program led Novogen scientists to speculate that the same compounds might be equally effective against abnormally-behaving stem cells associated with common degenerative diseases.

“The more we work with cancer stem cells, the more we have come to suspect that the action of our drugs is not so much the fact that the stem cells are cancerous, but that they are behaving abnormally. It was this suspicion that led us to this pilot study looking at their effect on abnormal stem cells responsible for causing degenerative diseases.”

“This early data completely supports our hypothesis. This is an exciting discovery for the Company and one that considerably expands its commercial scope. Our immediate focus will always be on the development of anti-cancer drugs, but this discovery cannot be ignored given the life-disrupting seriousness of many genetic and degenerative disorders.”

“As a result of this discovery, we now are committing the necessary resources to take this program to its next phase, which is to design and screen drugs against a wide range of stem cells associated with diseases such as cystic fibrosis, muscular dystrophy, Fragile X, Huntington’s Disease and Alzheimer’s Disease,” he added.


Dr Kelly said destroying the aberrant stem cells was an important first step toward eventually being able to successfully treat these kinds of conditions.

Dr Uli Schmidt, General Manager of Genea Biocells said, ”We made the effort to establish our stem cell technologies for this very reason - to use it as a resource to screen drugs in the hope of developing therapies for genetic disorders,”

“Being able to selectively modulate disease-affected stem and progenitor cells is a highly interesting observation that will help us better understand and potentially design treatments for such disorders” Schmidt added.



About Novogen
Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol ‘NRT’) and NASDAQ (symbol ‘NVGN’). The Company is based in Sydney, Australia and is focused on the development of novel anti-cancer drugs based on two proprietary drug technologies - the super-benzopyran chemical family and anti-tropomyosin drug technology.
About Genea Biocells
Genea Biocells Pty Ltd develops unique human stem cell tools to advance research and drug discovery in areas of unmet medical need. Genea Biocells partners with industry for custom-developed cell-based assay solutions in drug development and supplies application-ready, disease-affected and control differentiated cell types, including neurons and skeletal muscle. Genea Biocells is a subsidiary of fertility group Genea, a public, unlisted company that has been operating IVF clinics in Australia since 1985..




About Pluripotent stem cells
Human pluripotent stem cells can be expanded indefinitely in the laboratory and have the potential to differentiate to all cell types found in the human body. When derived from patients or embryos carrying genetic diseases they present an invaluable resource to study mechanisms causing disease and to test pharmacological properties of drug candidates.

 
arty
post Posted: Nov 14 2013, 03:17 PM
  Quote Post


Posts: 13,078
Thanks: 3381


In Reply To: arty's post @ Nov 14 2013, 12:05 PM

Could this be the next PSY?
I haven't followed the chatter on HC, but the chart certainly smells like P&D.

Attached Image
Let's see how they treat it tomorrow rolleyes.gif



--------------------
I trade daily, but I am not a licensed adviser. Whether you find my ideas reasonable or not: The only person responsible for your actions is YOU.
I follow two rules: (1) There are no sacred truths. All assumptions must be critically examined. Arguments from authority are worthless. (2) Whatever is inconsistent with observed facts must be discarded or revised. We must understand the Market as it is and not confuse how it is with how we wish it to be. (inspired by Carl Sagan)
 
rozz
post Posted: Nov 14 2013, 12:59 PM
  Quote Post


Posts: 302
Thanks: 20


In Reply To: arty's post @ Nov 14 2013, 12:05 PM

Hi Arty,


Yes Biotechs being rewarded with good news.


If you missed Nrt maybe have a look at Cdy .


Will break 5 cents soon, then its anybodys guess.

 
arty
post Posted: Nov 14 2013, 12:05 PM
  Quote Post


Posts: 13,078
Thanks: 3381


In Reply To: applefoot's post @ Nov 7 2013, 12:26 AM

Today's announcement: http://www.asx.com.au/asx/statistics...idsId=01465615
caused quite a stir. An entry sometime in October would have been interesting.
Attached thumbnail(s)
Attached Image


 




--------------------
I trade daily, but I am not a licensed adviser. Whether you find my ideas reasonable or not: The only person responsible for your actions is YOU.
I follow two rules: (1) There are no sacred truths. All assumptions must be critically examined. Arguments from authority are worthless. (2) Whatever is inconsistent with observed facts must be discarded or revised. We must understand the Market as it is and not confuse how it is with how we wish it to be. (inspired by Carl Sagan)
 
 


441 Pages (Click to Jump) V  < 1 2 3 4 5 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING